{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:24:06Z","timestamp":1784809446177,"version":"3.55.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Motivation<\/jats:title>\n                    <jats:p>Prostate cancer shows substantial clinical and molecular heterogeneity, limiting the prognostic accuracy of conventional clinicopathologic models. Single-gene alterations and tumor mutational burden provide limited prognostic discrimination. Pathway-level genomic abstraction may better capture cumulative oncogenic disruption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Genomic and clinical data from 2231 prostate adenocarcinoma patients were analyzed by mapping somatic mutations to 11 cancer-related signaling pathways. A composite pathway-based risk score integrating pathway burden, p53 pathway status, and high-risk co-alterations was developed and evaluated using survival analysis, Cox regression, time-dependent receiver operating characteristic curves, and machine-learning models, with generalizability assessed in an independent external cohort. The score stratified patients into distinct risk groups with significantly different overall survival (log-rank P &amp;lt; .0001); each one-point increase was associated with a 31% higher mortality risk (hazard ratio 1.31, 95% confidence interval 1.21\u20131.42). The model showed moderate discrimination (concordance index 0.5897) and more stable predictive performance than tumor mutational burden alone. Machine-learning models achieved similar performance, and feature importance analysis identified p53 pathway disruption and pathway burden as key predictors. The proposed framework is a mutation-based genomic risk-stratification tool derived from targeted-sequencing data that provides interpretable prognostic stratification with performance comparable to machine-learning models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Availability and implementation<\/jats:title>\n                    <jats:p>Available upon request.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bioadv\/vbag093","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:43:00Z","timestamp":1774528980000},"source":"Crossref","is-referenced-by-count":1,"title":["From pathways to prediction: a comparative machine learning framework for prostate cancer survival"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5358-3444","authenticated-orcid":false,"given":"Elif Kardelen","family":"\u00c7a\u011fda\u015f","sequence":"first","affiliation":[{"name":"Institute of Biotechnology, Ankara University , Ankara, 06135,","place":["T\u00fcrkiy"]},{"name":"Department of Pathology, Afyonkarahisar State Hospital , Afyonkarahisar, 03030,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"\u015ean","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ankara Bilkent City Hospital , Ankara, 06800,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkay","family":"\u00c7a\u011fda\u015f","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Afyonkarahisar State Hospital , Afyonkarahisar, 03030,","place":["T\u00fcrkiye"]},{"name":"Institute of Nuclear Sciences, Ege University , \u0130zmir, 35100,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Haf\u0131zo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Afyonkarahisar State Hospital , Afyonkarahisar, 03030,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"2026050508283691600_vbag093-B1","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026050508283691600_vbag093-B2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research Network","year":"2015","journal-title":"Cell"},{"key":"2026050508283691600_vbag093-B3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2026050508283691600_vbag093-B4","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1158\/2767-9764.CRC-24-0210","article-title":"Prostate cancer progression modeling provides insight into dynamic molecular changes associated with progressive disease states","volume":"4","author":"Chen","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2026050508283691600_vbag093-B5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"2026050508283691600_vbag093-B6","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J Urol"},{"key":"2026050508283691600_vbag093-B7","first-page":"S13","article-title":"The evolving landscape of prostate cancer somatic mutations","volume":"82 Suppl 1","author":"Cotter","year":"2022","journal-title":"Prostate"},{"key":"2026050508283691600_vbag093-B8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-3-642-45195-9_17","article-title":"Distinguishing indolent from aggressive prostate cancer","volume":"202","author":"Culig","year":"2014","journal-title":"Recent Results Cancer Res"},{"key":"2026050508283691600_vbag093-B9","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1001\/jamaoncol.2020.4922","article-title":"Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the international staging collaboration for cancer of the prostate","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026050508283691600_vbag093-B10","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s43018-024-00787-0","article-title":"Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer","volume":"5","author":"Fernandez-Mateos","year":"2024","journal-title":"Nat Cancer"},{"key":"2026050508283691600_vbag093-B11","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2026050508283691600_vbag093-B12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.euros.2024.10.008","article-title":"Prognostic expression signature of RB1, PTEN, and TP53 genes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor pathway inhibitors","volume":"70","author":"Garcia de Herreros","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"2026050508283691600_vbag093-B13","volume-title":"Prostate Cancer","author":"Giona","year":"2021"},{"key":"2026050508283691600_vbag093-B14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026050508283691600_vbag093-B15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"key":"2026050508283691600_vbag093-B16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/MOU.0000000000000419","article-title":"Genomic testing for localized prostate cancer: where do we go from here?","volume":"27","author":"Loeb","year":"2017","journal-title":"Curr Opin Urol"},{"key":"2026050508283691600_vbag093-B17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12859-024-05981-6","article-title":"ClassifieR 2.0: expanding interactive gene expression-based stratification to prostate and high-grade serous ovarian cancer","volume":"25","author":"McCabe","year":"2024","journal-title":"BMC Bioinformatics"},{"key":"2026050508283691600_vbag093-B18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13046-022-02255-y","article-title":"Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation","volume":"41","author":"Merkens","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2026050508283691600_vbag093-B19","doi-asserted-by":"crossref","first-page":"107669","DOI":"10.1016\/j.celrep.2020.107669","article-title":"Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress","volume":"31","author":"Nyquist","year":"2020","journal-title":"Cell Rep"},{"key":"2026050508283691600_vbag093-B20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/cancers17040645","article-title":"TP53 deficiency in the natural history of prostate cancer","volume":"17","author":"Ofner","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026050508283691600_vbag093-B21","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.3390\/ijms26115309","article-title":"Integrating aggressive-variant prostate cancer-associated tumor suppressor gene status with clinical variables to refine prognosis and predict androgen receptor pathway inhibitor response in metastatic hormone-sensitive setting","volume":"26","author":"Pedrani","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026050508283691600_vbag093-B22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN guidelines insights: prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"2026050508283691600_vbag093-B23","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026050508283691600_vbag093-B24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1101\/gad.315739.118","article-title":"Genetics and biology of prostate cancer","volume":"32","author":"Wang","year":"2018","journal-title":"Genes Dev"},{"key":"2026050508283691600_vbag093-B25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12894-021-00795-7","article-title":"Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Urol"},{"key":"2026050508283691600_vbag093-B26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.urolonc.2017.12.022","article-title":"Molecular correlates of intermediate- and high-risk localized prostate cancer","volume":"36","author":"Ye","year":"2018","journal-title":"Urol Oncol"},{"key":"2026050508283691600_vbag093-B27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41391-021-00325-4","article-title":"A comparative study of PCS and PAM50 prostate cancer classification schemes","volume":"24","author":"Yoon","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026050508283691600_vbag093-B28","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["Bioinformatics Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bioinformaticsadvances\/advance-article-pdf\/doi\/10.1093\/bioadv\/vbag093\/67631301\/vbag093.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformaticsadvances\/article-pdf\/6\/1\/vbag093\/67631301\/vbag093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformaticsadvances\/article-pdf\/6\/1\/vbag093\/67631301\/vbag093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:28:44Z","timestamp":1777984124000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bioinformaticsadvances\/article\/doi\/10.1093\/bioadv\/vbag093\/8554151"}},"subtitle":[],"editor":[{"given":"Mikhail","family":"Dozmorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/bioadv\/vbag093","relation":{},"ISSN":["2635-0041"],"issn-type":[{"value":"2635-0041","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"vbag093"}}